What are the main risks for Moderna stock?

Moderna faces declining COVID-19 vaccine revenue, competitive pressure, and depends on pipeline expansion success.

Has Recursion achieved profitability yet?

No, Recursion is not yet profitable and relies on funding from partnerships and investments.

What are Recursion's key partnerships?

Recursion has partnerships with Roche and Bayer in drug discovery.

How is Moderna expanding beyond vaccines?

Moderna is developing vaccines for other diseases like influenza and RSV, as well as rare disease treatments.

Moderna vs. Recursion: Which Pharma Stock Is Better in 2026?

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Investors in the pharmaceutical sector are eyeing two innovative companies: Moderna, which seeks to expand beyond vaccines, and Recursion, which relies on artificial intelligence for drug discovery. Each has a different strategy and distinct risks.

Moderna's Strategy

Moderna aims to diversify its portfolio after the success of its COVID-19 vaccine, developing vaccines for other diseases such as influenza and RSV, as well as rare disease treatments based on mRNA technology.

Recursion's Strategy

Recursion uses an AI platform to discover drugs faster and at lower cost. It has partnerships with major companies like Roche and Bayer, focusing on oncology and rare diseases.

Risk Comparison

Moderna: Faces declining revenue from its COVID-19 vaccine and competitive pressure from new vaccines. Success depends on expanding its pipeline.
Recursion: Still in a pre-revenue stage, relying on clinical trial success and partnerships. AI-driven drug discovery has yet to prove its viability on a large scale.

Financial Performance

Moderna: Generated massive revenues during the pandemic but is now trending downward. It has significant cash reserves to invest in R&D.
Recursion: Not yet profitable, relying on funding from partnerships and investments. Operating losses are high.

What This Means for Investors

Choosing the right stock depends on the investor's goals and risk tolerance. Moderna may be less risky due to its strong financial base, while Recursion offers higher growth potential with greater risk. Diversification is recommended.